These studies provide clinicians treating tuberculosis patients with a basis for understanding variable natural history and the opportunity to provide genotype-specific treatment depending on the functional levels of LTA4H (and its downstream target, tumor necrosis factor). This evidence concerns the gene LTA4H and tuberculosis.